Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Am Coll Cardiol ; 31(7): 1466-73, 1998 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-9626821

RESUMEN

OBJECTIVES: We sought to compare platelet characteristics after reteplase and alteplase therapy in the setting of the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)-III trial. BACKGROUND: Platelet function may be impaired during thrombolysis in patients with an acute myocardial infarction. The effects of reteplase and alteplase on platelet aggregation and major surface antigen expression during the first 24 h of infarction therapy are unknown. METHODS: Platelet aggregation and receptor expression by flow cytometry were determined in 23 patients before thrombolysis and thereafter at 3, 6, 12 and 24 h. RESULTS: Aggregation was higher after reteplase at 24 h when induced by 5 micromol/liter adenosine diphosphate (ADP) (p = 0.007), 10 micromol/liter ADP (p = 0.02), collagen (p = 0.003) and thrombin (p = 0.009) than after alteplase. Reteplase therapy exhibited greater glycoprotein (GP) IIb/IIIa (p = 0.04), very late antigen-2 (p = 0.04) and platelet/endothelial cell adhesion molecule-I (p = 0.002) expression at 24 h. Trends toward decreased receptor expression early (3 to 6 h), followed by a progressive increase at 12 h and especially at 24 h occurred after both agents. CONCLUSIONS: In this prospective clinical ex vivo platelet study, similar patterns of platelet aggregation and surface receptor expression occurred during the first 24 h of coronary thrombolysis with reteplase and alteplase. However, after reteplase, indicators of platelet activity were higher at 24 h after thrombolysis than after alteplase. These data suggest that GP IIb/IIIa inhibitors or other antiplatelet strategies may be particularly advantageous when used 12 to 24 h after thrombolysis, especially after reteplase therapy. It is at this time point during the first day of coronary thrombolysis that GP IIb/IIIa is markedly expressed and platelets are most active.


Asunto(s)
Antígenos de Superficie , Plaquetas/inmunología , Fibrinolíticos/farmacología , Infarto del Miocardio/tratamiento farmacológico , Activadores Plasminogénicos/farmacología , Agregación Plaquetaria/efectos de los fármacos , Terapia Trombolítica , Activador de Tejido Plasminógeno/farmacología , Adulto , Anciano , Plaquetas/efectos de los fármacos , Femenino , Fibrinolíticos/uso terapéutico , Citometría de Flujo , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/sangre , Infarto del Miocardio/fisiopatología , Activadores Plasminogénicos/uso terapéutico , Estudios Prospectivos , Ensayos Clínicos Controlados Aleatorios como Asunto , Proteínas Recombinantes/farmacología , Proteínas Recombinantes/uso terapéutico , Estadísticas no Paramétricas , Activador de Tejido Plasminógeno/uso terapéutico
2.
Mol Endocrinol ; 10(6): 694-704, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8776729

RESUMEN

We have examined the ability of estrogen receptor (ER) to bind and bend DNA fragments containing the Xenopus laevis vitellogenin A2 estrogen response element (ERE), which contains a palindromic, consensus ERE sequence, the X. laevis vitellogenin B1 ERE2, which contains a 1-bp mismatch in the 5'-end of the half-palindrome, and the human pS2 ERE, which contains a 1-bp mismatch in the 3'-end of the half-palindrome. ER binding induced a 65 degrees bend in DNA fragments containing the consensus ERE, the vitellogenin B1 ERE2, or the pS2 ERE. However, ER affinity for the consensus ERE was 2-fold greater than for either the vitellogenin B1 ERE2 or the pS2 ERE. When Chinese hamster ovary (CHO) cells were transfected with reporter plasmids containing either the consensus ERE, the vitellogenin B1 ERE2, or the pS2 ERE separated from the TATA sequence by 26 helical turns, exposure to 10 nm 17 beta-estradiol increased transcription 12.7-, 2.4-, and 3.8-fold, respectively. Increasing the spacing between the ERE and TATA sequence to three helical turns decreased the ability of the consensus ERE to activate transcription by 55% and increased the ability of the pS2 ERE to activate transcription by 35% but had no significant effect on vitellogenin B1 ERE2 activity. Further increasing the distance between the ERE and TATA sequence to 3.6 helical turns restored the activity of promoters containing the consensus ERE and pS2 ERE but decreased the activity of the promoter containing the relatively weak vitellogenin B1 ERE2. These data support the idea that 1) the affinity of ER for the ERE, 2) the location of an ERE within the promoter, and 3) the magnitude and orientation of DNA bends induced by binding of ER or other proteins are important in transcription activation of estrogen-responsive genes.


Asunto(s)
Proteínas del Huevo , Proteínas , Receptores de Estrógenos/genética , Receptores de Estrógenos/metabolismo , Transcripción Genética , Animales , Secuencia de Bases , Sitios de Unión , Células CHO/metabolismo , Secuencia Conservada , Cricetinae , Regulación de la Expresión Génica , Genes Reporteros , Humanos , Proteínas de Neoplasias/metabolismo , Conformación de Ácido Nucleico , Regiones Promotoras Genéticas , Receptores de Superficie Celular/metabolismo , Receptores de Estrógenos/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Homología de Secuencia de Ácido Nucleico , Activación Transcripcional , Factor Trefoil-1 , Proteínas Supresoras de Tumor , Vitelogeninas/metabolismo , Xenopus laevis , Levaduras/genética , Levaduras/metabolismo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda